Polymorphism of immunomodulatory cytokine genes: Implications in acute renal failure

Blood Purification

Volumn 22, Issue 1, 2004, Pages 101-111

  Jaber, Bertrand L ^a   Liangos, Orfeas ^a   Pereira, Brian J G ^a   Balakrishnan, Vaidyanathapuram S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Acute renal failure; Cytokines; Infection; Inflammation; Interleukin 10; Mortality; Sepsis; Tumor necrosis factor

Indexed keywords

CISPLATIN; CYCLOSPORIN A; CYTOKINE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INTERLEUKIN 10; LYMPHOTOXIN; PENTOXIFYLLINE; ROLIPRAM; TACROLIMUS; THALIDOMIDE; THEOPHYLLINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE KIDNEY FAILURE; ALLELE; ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DOWN REGULATION; DRUG MECHANISM; GENE LOCUS; GENETIC MARKER; GENOTYPE; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INTRON; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; REVIEW; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-10; ISCHEMIA; KIDNEY; KIDNEY FAILURE, ACUTE; POLYMORPHISM, GENETIC; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0942278984     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074930     Document Type: Review

References (123)

1. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT: Hospital-acquired renal insufficiency: A prospective study. Am J Med 1983;74:243-248.
2. Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 1996;334:1448-1460.
3. Nolan CR, Anderson RJ: Hospital-acquired acute renal failure. J Am Soc Nephrol 1998;9:710-718.
4. Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
5. McCarthy JT: Prognosis of patients with acute renal failure in the intensive-care unit: A tale of two eras. Mayo Clin Proc 1996;71:117-126.
6. Mehta R, McDonald B, Gabbai F, Pahl M, Pascual M, Farkas A, Kaplan M; Collaborative Group for Treatment of ARF in the ICU: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001;60:1154-1163.
7. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: A cohort analysis. JAMA 1996;275:1489-1494.
8. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343-348.
9. Centers for Disease Control: Increases in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 1990;39:31-34.
10. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;13:818-822.
12. Opal S, DePalo V: Anti-inflammatory cytokines. Chest 2000;117:1162-1172.
13. De Waal Malefyt F, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
14. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822.
15. Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002;30(suppl):S58-S63.
16. van der Poll T JJ, Levi M, ten Cate H, ten Cate JW, van Deventer SJ: Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994;180:1985-1988.
17. Perianayagam M, Jaber B, Guo D, King A, Pereira B, Balakrishnan V: Defective interleukin-10 synthesis by peripheral blood mononuclear cells among hemodialysis patients. Blood Purif 2002;20:543-550.
18. Donnelly RP, Freeman SL, Hayes MP: Inhibition of IL-10 expression by IFN-γ-regulates transcription of TNF-α in human monocytes. J Immunol 1995;155:1420-1427.
19. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994;153:811-816.
20. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL: Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-3569.
21. Gunnett CA, Heistad DD, Berg DJ, Faraci FM: IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart Circ Physiol 2000;279:H1555-H1562.
22. Haddad J, Fahlman C: Redox- and oxidant-mediated regulation of interleukin-10: An anti-inflammatory, antioxidant cytokine? Biochem Biophys Res Commun 2002;29:163-176.
23. Tabardel Y, Duchateau J, Schmartz D, Marecaux G, Shahla M, Barvais L, Leclerc JL, Vincent JL: Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76-80.
24. Fillinger MP, Rassias AJ, Guyre PM, Sanders JH, Beach M, Pahl J, Watson RB, Whalen PK, Yeo KT, Yeager MP: Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth 2002; 16:163-169.
25. Wiecek A, Zeier M, Ritz E: Role of infection in the genesis of acute renal failure. Nephrol Dial Transplant 1994;9:40-44.
26. Santos OFP, Boim MA, Schor N: Acute renal failure and sepsis - Pathophysiology. Kidney: A Current Survey of World Literature 1995;4:59-62.
27. Groeneveld AB: Pathogenesis of acute renal failure during sepsis. Nephrol Dial Transplant 1994;4:47-51.
28. Fouqueray B, Philippe C, Herbelin A, Perez J, Ardaillou R, Baud L: Cytokine formation within rat glomeruli during experimental endotoxemia. J Am Soc Nephrol 1993;3:1783-1791.
29. Kohan DE: Role of endothelin and tumour necrosis factor in the renal response to sepsis. Nephrol Dial Transplant 1994;9:73-77.
30. Kohan DE: Production of endothelin-1 by rat mesangial cells: Regulation by tumor necrosis factor. J Lab Clin Med 1992;119:477-484.
31. Cunningham P, Dyanov H, Park P, Wang J, Newell K, Quigg R: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168:5817-5823.
32. Flo TH, Halaas O, Torp S, Ryan L, Lien E, Dybdahl B, Sundan A, Espevik T: Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol 2001;69:474-481.
33. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A: Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105:685-690.
34. Bonventre J, Weinberg J: Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003;14:2199-2210.
35. Linas SL, Whitteburg D, Parsons PE, Repine JE: Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 192;42:610-616.
36. Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, Imberti B, Te Loo M, Monnens L, Remuzzi G, Morigi M: Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-IB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002;62:846-856.
37. Solez K, Morel-Maroger L, Sraer J-D: The morphology of acute tubular necrosis in man: Analysis of 57 renal biopsies and a comparison with glycerol model. Medicine 1979;58:362-376.
38. Karsou SA, Jaber BL, Pereira BJ: Impact of intermittent hemodialysis variables on clinical outcomes in acute renal failure: A critical review. Am J Kidney Dis 2000;35:980-991.
39. Sheridan AM, Bonventre JV: Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 2000;9:427-434.
40. Burne M, Daniels F, El Ghandour A, Mauiyyedi S, Colvin R, O'Donnell M, Rabb H: Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001;108:1283-1290.
41. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001;60:2118-2128.
42. Ramesh G, Reeves W: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-842.
43. Burne-Taney M, Kofler J, Yokota N, Weisfeldt M, Traystman R, Rabb H: Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury. Am J Physiol Renal Physiol 2003;285:F87-F94.
44. Kelly KJ, Williams WWJ, Colvin RB, Bonventre JV: Antibody to inter-cellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994;91:812-816.
45. Huang X, Kitching A, Tipping P, Holdsworth S: Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 2000;11:262-269.
46. Kitching A, Katerelos M, Mudge S, Tipping P, Power D, Holdsworth S: Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol 2002;128:36-43.
47. Gormley SM, McBride WT, Armstrong MA, Young IS, McClean E, MacGowan SW, Campalani G, McMurray TJ: Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery. Anesthesiology 2000; 93:1210-1216.
48. Gormley SM, McBride WT, Armstrong MA, McClean E, MacGowan SW, Campalani G, McMurray TJ: Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass. Cytokine 2002;17:61-65.
49. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62: 237-244.
50. Himmelfarb J, Sezer M, Shyr Y, Freedman S, Ikizler T, Becker K, Spratt D, Group PS: A prospective analysis of pro-inflammatory and anti-inflammatory cytokines in patients with acute renal failure (abstract). J Am Soc Nephrol 2002;13:5A.
51. Iglesias J, Marik PE, Levine JS, Norasept II Study Investigators: Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003;41:62-75.
52. Loisa P, Rinne T, Laine S, Hurme M, Kaukinen S: Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 2000;47:319-325.
53. Venter J, Adams M, Myers E: The sequence of the human genome. Science 2001;291:1304-1351.
54. Guttmacher A, Collins F: Genomic medicine -A primer. N Engl J Med 2002;347:1512-1520.
55. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott M, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: On-line databases, supplement 1. Genes Immun 2001;2:61-70.
56. Haukim N, Bidwell J, Smith A, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott M, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: On-line databases, supplement 2. Genes Immun 2002;3:313-330.
57. Genetic variation in individuals: Mutation and polymorphism, in Nussbaum R, McInnes R, Willard H (eds): Thompson & Thompson Genetics in Medicine, ed 6. Philadelphia, Saunders, 2001, pp 79-94.
58. van Deventer S: Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 2000;26(suppl 1):S98-S102.
59. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW: An allelic polymorphism within the human tumor necrosis factor-alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-560.
60. Abraham LJ, Kroeger KM: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: Relevance to disease. J Leukoc Biol 1999;66:562-566.
61. Morse H, Olomolaiye O, Wood N, Keen L, Bidwell J: Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 1999;11:789-795.
62. Wilson AG, Symons JA, McDowell TL, McDewitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
63. Kroeger KM, Carville KS, Abraham LJ: The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 1997;34:391-399.
64. Warzocha K, Ribeiro P, Bienvenu J: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998;91:3574-3581.
65. Louis E, Franchimont D, Piron A: Tumor necrosis factor gene polymorphism influences TNF-alpha production in lipopolysaccharide-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-406.
66. Abraham L, Du D, Zahedi K, Dawkins R, Whitehead A: Haplotypic polymorphisms of the TNFβ gene. Immunogenetics 1991;33:50-53.
67. Pociot F, Molvig J, Wogensen L, Worsaae H, Dalboge H, Baek L, Nerup J: A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 1991;33:37-49.
68. Tabrizi A, Zehnbauer B, Freeman B, Buchman T: Genetic markers in sepsis. J Am Coll Surg 2001;192:106-117.
69. Fugger L, Morling N, Ryder L, Georgsen J, Jakobsen B, Svejgaard A, Andersen V, Oxholm P, Karup Pedersen F, Friis J, et al: NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNF α) region in four autoimmune diseases. Tissue Antigens 1989;34:17-22.
70. Messer G, Spengler U, Jung M, Honold G, Blomer K, Pape G, Riethmuller G, Weiss E: Polymorphic structure of the tumor necrosis factor (TNF) locus: An NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991;173:209-219.
71. Heesen M, Kunz D, Bachmann-Mennenga B, Merk H, Bloemeke B: Linkage disequilibrium between tumor necrosis factor (TNF)-α-308 G/ A promoter and TNF-beta NcoI polymorphisms: Association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 2003;31:211-214.
72. Mira J-P, Cariou A, Grall F, Delclaux C, Losser M-R, Heshmati F, Cheval C, Monchi M, Teboul J-L, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut J-F: Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999;282:561-568.
73. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, Lui WY, Chiu JH, Lee TY: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000;28:2733-2736.
74. Weitkamp JH, Stuber F, Bartmann P: Pilot study assessing TNF gene polymorphism as a prognostic marker for disease progression in neonates with sepsis. Infection 2000;28:92-96.
75. Nadel S, Newport MJ, Booy R, Levin M: Variation in the tumor necrosis factor-α promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878-880.
76. Mcguire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D: Variation of the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-510.
77. Cabrera M, Shaw MA, Sharples C: Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995;182:1259-1264.
78. Wunderink RG, Waterer GW, Cantor RM, Quasney MW: Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 2002;121:87S.
79. Stuber F, Petersen M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384.
80. Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D, Schade FU, Stuber F: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999;230:207-214.
81. Waterer G, ElBahlawan L, Quasney M, Zhang Q, Kessler L, Wunderink R: Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med 2003;31:1367-1372.
82. Pelletier R, Pravica V, Perrey C, Xia D, Ferguson RM, Hutchinson I, Orosz C: Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000;70:674-680.
83. McGuire W, Knight J, Hill A, Allsopp C, Greenwood B, Kwiatkowski D: Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 1999;179:287-290.
84. Zhang D, Li J, Jiang Z, Yu B, Tang X: Association of two polymorphisms of tumor necrosis factor gene with acute severe pancreatitis. J Surg Res 2003;112:138-143.
85. Schroeder S, Borger N, Wrigge H, Welz A, Putensen C, Hoeft A, Stuber F: A tumor necrosis factor gene polymorphism influences the inflammatory response after cardiac operation. Ann Thorac Surg 2003;75:534-537.
86. Yende S, Quasney M, Zhang Q, Frederick K, Kessler L, Wunderink RG: Impact of cytokine gene polymorphisms on outcomes of coronary artery bypass graft surgery. Chest 2002;121:86S.
87. Yende S, Quasney MW, Tolley E, Zhang Q, Wunderink RG: Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery. Crit Care Med 2003;31:133-140.
88. Shaikh K, Yende S, Waterer GW, Quasney M, Wunderink R: Effect of tumor necrosis factor gene polymorphisms on restoration of body temperature after coronary artery bypass graft surgery. Chest 2000;118:109S.
89. Treszl A, Toth-Heyn P, Kocsis I, Nobilis A, Schuler A, Tulassay T, Vasarhelyi B: Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol 2002;17:713-717.
90. Guo D, Rao M, Balakrishnan V, Pereira B, Jaber B: Cytokine gene polymorphisms in patients with dialysis-requiring acute renal failure. J Am Soc Nephrol 2002;13:5A.
91. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP, Vandenbrouke JP: Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-173.
92. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes of the interleukin-10 5)flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101-1108.
93. Keijsers V, Verweij C, Westendorp R, et al: IL-10 promotor haplotypes: Discrepancy between lack of functionality in transfection assays and skewed distribution in meningococcal disease. Genes Immun 1999;1:78-79.
94. van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V, de Straat FG, Westerdaal NA, de Winkel JG, Westendorp RG: Relevance of FcA receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001;184:1548-1555.
95. Gallagher P, Lowe G, Fitzgerald T, Bella A, Greene C, McElvaney N, O'Neill S: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003;58:154-156.
96. Delgado J, Baena A, Thim S, Goldfeld A: Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis 2002;186:1463-1468.
97. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003;31:34-38.
98. Nabel E: Genomic medicine: Cardiovascular disease. N Engl J Med 2003;349:60-72.
99. Ridker P, Stampfer M: Assessment of genetic markers for coronary thrombosis: Promise and precaution. Lancet 1999;353:687-688.
100. Newman TB, Browner WS, Hulley SB: Enhancing causal inference in observational studies; in Hulley SB, Cummings SR (eds): Designing Clinical Research. Baltimore, Wil-liams & Wilkins, 1988, pp 98-109.
101. Marx J: How the glucorticoids suppress immunity. Science 1995;270:232-233.
102. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-IB activity through induction of IIB synthesis. Science 1995;270:286-290.
103. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin ASJ: Role of transcriptional activation of IκBa in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-286.
104. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-394.
105. Strieter RM, Remick DG, Ward PA: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-1236.
106. Doherty GM, Jensen JC, Alexander H, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991;110:192-198.
107. Parry G, Mackman N: Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J Immunol 1997;159:5450-5456.
108. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr H, Endres S: Specific type IV phospho-diesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000;292:22-30.
109. Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-production by human mononuclear cells. Int J Immunopharmacol 1993;15:409-413.
110. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
111. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-1680.
112. Moore K, de Waal M, Coffman R, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;765:683-765.
113. Pajkrt D, Camoglio L, Tielvan Buul M, de Bruin K, Cutler D, Affrime M, Rikken G, van der Poll T, ten Cate J, van Deventer S: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration. J Immunol 1997;158: 3971-3977.
114. Calabrese L: Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21:241-248.
115. Bermudez LE, Wu M, Young LS: Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor. Lymphokine Res 1990;9:137-145.
116. Platzer C, Fritsch E, Elsner T, Lehmann M, Volk H, Prosch S: Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur J Immunol 1999;29:3098-3104.
117. Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C: cAMP-induced interleukin-10 promoter activation depends on CCAAT/enhancer- binding protein expression and monocytic differentiation. J Biol Chem 2003;278:5597-5604.
118. Escofier N, Boichot E, Germain N, Silva P, Martins M, Lagente V: Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. Fundam Clin Pharmacol 1999;13:96-101.
119. Mascali J, Cvietusa P, Negri J, Borish L: Anti-inflammatory effects of theophylline: Modulation of cytokine production. Ann Allergy Asthma Immunol 1996;77:34-38.
120. Peleman R, Kips J, Pauwels R: Therapeutic activities of theophylline in chronic obstructive pulmonary disease. Clin Exp Allergy 1998;28(suppl 3):53-56.
121. Eigler A, Siegmund B, Emmerich U, Baumann K, Hartmann G, Endres S: Anti-inflammatory activities of cAMP-elevating agents: Enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998;63:101-107.
122. van Furth A, Seijmonsbergen E, Langermans J, van der Meide P, van Furth R: Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1 beta (IL-1 beta), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995;2:689-692.
123. Cho M, Kim W, Min S, Min D, Min J, Lee S, Park S, Cho C, Kim H: Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. Arthritis Rheum 2002;46:42-51.